Published in Cancer Drug Deliv on January 01, 1984
Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother (2002) 1.79
The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis (2008) 1.62
Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate. Antimicrob Agents Chemother (1989) 1.48
Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob Agents Chemother (1989) 1.48
Delivery of negatively charged liposomes into the atherosclerotic plaque of apolipoprotein E-deficient mouse aortic tissue. J Liposome Res (2014) 1.40
Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob Agents Chemother (1991) 1.39
Roles of liposome composition and temperature in distribution of amphotericin B in serum lipoproteins. Antimicrob Agents Chemother (1993) 1.32
Liposomes as carriers of antimicrobial agents. Antimicrob Agents Chemother (1987) 1.28
Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections. Antimicrob Agents Chemother (1987) 1.26
Concentrations in serum and distribution in tissue of free and liposomal amphotericin B in rats during continuous intralipid infusion. Antimicrob Agents Chemother (1994) 1.19
Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrob Agents Chemother (1992) 1.14
Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies. Antimicrob Agents Chemother (1998) 1.08
Diversity of lipid-based polyene formulations and their behavior in biological systems. Eur J Clin Microbiol Infect Dis (1997) 0.96
Physical characteristics and lipoprotein distribution of liposomal nystatin in human plasma. Antimicrob Agents Chemother (1997) 0.94
Plasma lipoprotein distribution of liposomal nystatin is influenced by protein content of high-density lipoproteins. Antimicrob Agents Chemother (1998) 0.92
Liposome encapsulation of clofazimine reduces toxicity in vitro and in vivo and improves therapeutic efficacy in the beige mouse model of disseminated Mycobacterium avium-M. intracellulare complex infection. Antimicrob Agents Chemother (1996) 0.88
Limited protection by small unilamellar liposomes against the renal tubular toxicity induced by repeated amphotericin B infusions in rats. Antimicrob Agents Chemother (1991) 0.88
Compartmental pharmacokinetics and tissue distribution of multilamellar liposomal nystatin in rabbits. Antimicrob Agents Chemother (2000) 0.85
Improvement of amphotericin B activity during experimental cryptococcosis by incorporation into specific immunoliposomes. Antimicrob Agents Chemother (1990) 0.84
Activity against rhinoviruses, toxicity, and delivery in aerosol of enviroxime in liposomes. Antimicrob Agents Chemother (1988) 0.83
Prophylaxis of murine candidiasis via application of liposome-encapsulated amphotericin B and a muramyl dipeptide analog, alone and in combination. Antimicrob Agents Chemother (1985) 0.82
Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities. Antimicrob Agents Chemother (2001) 0.82
Evaluation of renal toxicity and antifungal activity of free and liposomal amphotericin B following a single intravenous dose to diabetic rats with systemic candidiasis. Antimicrob Agents Chemother (1996) 0.81
Effect of fasting on temporal variation in the nephrotoxicity of amphotericin B in rats. Antimicrob Agents Chemother (1999) 0.75
Suspected Pulmonary Infection with Trichoderma longibrachiatum after Allogeneic Stem Cell Transplantation. Intern Med (2017) 0.75
Multifractality in human heartbeat dynamics. Nature (1999) 4.20
Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J Infect Dis (1983) 3.86
Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med (2013) 2.75
Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis (1985) 2.64
Biopsy of the prostate guided by transrectal ultrasound: relation between warfarin use and incidence of bleeding complications. Clin Radiol (2005) 2.39
Heartbeat synchronized with ventilation. Nature (1998) 2.29
Scaling behaviour of heartbeat intervals obtained by wavelet-based time-series analysis. Nature (1996) 2.26
Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochim Biophys Acta (1984) 2.21
Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. AJNR Am J Neuroradiol (2011) 2.00
Treatment of hepatosplenic candidiasis with liposomal-amphotericin B. J Clin Oncol (1987) 1.83
Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol (2001) 1.73
Liposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic mice. J Infect Dis (1984) 1.67
In vitro antifungal activities of amphotericin B and liposome-encapsulated amphotericin B. Antimicrob Agents Chemother (1984) 1.58
Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. Clin Infect Dis (2001) 1.48
Pharmacokinetics, tissue distribution, and toxicity of free and liposomal amphotericin B in diabetic rats. J Infect Dis (1990) 1.46
Synchronization in the human cardiorespiratory system. Phys Rev E Stat Phys Plasmas Fluids Relat Interdiscip Topics (1999) 1.46
Effects of sterols on the therapeutic efficacy of liposomal amphotericin B in murine candidiasis. Cancer Drug Deliv (1983) 1.43
Nutritional support after liver transplantation: a randomized prospective study. JPEN J Parenter Enteral Nutr (1990) 1.43
Acute dialysis quality initiative (ADQI). Nephrol Dial Transplant (2001) 1.42
Liposomal delivery of methylphosphonate antisense oligodeoxynucleotides in chronic myelogenous leukemia. Blood (1994) 1.41
Variables influencing tumor uptake of anti-melanoma monoclonal antibodies radioiodinated using para-iodobenzoyl (PIB) conjugate. J Nucl Med (1991) 1.39
Definition of an unexpected ligand recognition motif for alphav beta6 integrin. J Biol Chem (1999) 1.38
Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis. Antimicrob Agents Chemother (1987) 1.38
Nanomedicine based approaches for the delivery of siRNA in cancer. J Intern Med (2010) 1.36
Distribution and functional consequences of nucleotide polymorphisms in the 3'-untranslated region of the human Sep15 gene. Cancer Res (2001) 1.35
Roles of liposome composition and temperature in distribution of amphotericin B in serum lipoproteins. Antimicrob Agents Chemother (1993) 1.32
Experimental Trichosporon infection in persistently granulocytopenic rabbits: implications for pathogenesis, diagnosis, and treatment of an emerging opportunistic mycosis. J Infect Dis (1992) 1.30
Liposomes as carriers of antimicrobial agents. Antimicrob Agents Chemother (1987) 1.28
Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections. Antimicrob Agents Chemother (1987) 1.26
Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22. Oncogene (2010) 1.26
Familial Hibernian fever. Q J Med (1982) 1.26
Interaction of nuclear proteins with an AP-1/CRE-like promoter sequence in the human TNF-alpha gene. J Leukoc Biol (1994) 1.24
Clinical pharmacology of 99mTc-labeled liposomes in patients with cancer. Cancer Res (1984) 1.23
Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys. Antimicrob Agents Chemother (1986) 1.22
Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B. Antimicrob Agents Chemother (1994) 1.20
Concentrations in serum and distribution in tissue of free and liposomal amphotericin B in rats during continuous intralipid infusion. Antimicrob Agents Chemother (1994) 1.19
Flavonoids as DNA topoisomerase antagonists and poisons: structure-activity relationships. J Nat Prod (1995) 1.18
Cardiopulmonary toxicity after liposomal amphotericin B infusion. Ann Intern Med (1991) 1.17
Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice. Antimicrob Agents Chemother (1997) 1.16
Prophylaxis of Candida albicans infection in neutropenic mice with liposome-encapsulated amphotericin B. Antimicrob Agents Chemother (1984) 1.15
Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: role of lipid transfer protein. J Pharm Sci (1994) 1.15
Iniencephaly with several rare associated anomalies. Indian Pediatr (1982) 1.13
Self-expanding stents for recanalization of acute cerebrovascular occlusions. AJNR Am J Neuroradiol (2007) 1.13
Effect of liposomal amphotericin B on murine macrophages and lymphocytes. Infect Immun (1985) 1.12
Isolation and structure determination of Pachybasium cerebrosides which potentiate the antifungal activity of aculeacin. J Antibiot (Tokyo) (1988) 1.10
Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients. Cancer Res (1985) 1.10
The 3rd International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI). Int J Artif Organs (2005) 1.09
Treatment of invasive Aspergillus sinusitis with liposomal-amphotericin B. Laryngoscope (1987) 1.09
Use of in vitro assays to predict the efficacy of chemopreventive agents in whole animals. J Cell Biochem Suppl (1996) 1.08
SNAP-29: a general SNARE protein that inhibits SNARE disassembly and is implicated in synaptic transmission. Proc Natl Acad Sci U S A (2001) 1.08
Spatial learning and memory as a function of age in the dog. Behav Neurosci (1995) 1.07
Hepatic and serum copper in Indian childhood cirrhosis. Indian Pediatr (1981) 1.06
Capsaicin causes cell-cycle arrest and apoptosis in ER-positive and -negative breast cancer cells by modulating the EGFR/HER-2 pathway. Oncogene (2009) 1.06
Comparative chemopreventive mechanisms of green tea, black tea and selected polyphenol extracts measured by in vitro bioassays. Carcinogenesis (2000) 1.05
The failing Fontan circulation: successful conversion of atriopulmonary connections. J Thorac Cardiovasc Surg (2004) 1.03
Fructose and carbonyl metabolites as endogenous toxins. Chem Biol Interact (2008) 1.01
Inhibition of HIV replication by liposomal encapsulated amphotericin B. Antiviral Res (1989) 1.01
Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver. Oncogene (2008) 1.01
Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells. Oncogene (1999) 1.01
Role of vascular congestion in cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant (1992) 1.00
Selective toxicity and enhanced therapeutic index of liposomal polyene antibiotics in systemic fungal infections. Ann N Y Acad Sci (1985) 1.00
Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies. Antimicrob Agents Chemother (1997) 1.00
The effects of race on diagnosis and disposition from a psychiatric emergency service. J Clin Psychiatry (1995) 1.00
Expression of tissue transglutaminase in cultured monocytic leukemia (THP-1) cells during differentiation. Cancer Res (1986) 0.99
Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin Cancer Res (2001) 0.99
Fusarium. A newly recognized fungal pathogen in immunosuppressed patients. Cancer (1986) 0.98
The body mass index is a less-sensitive tool for detecting cases with obesity-associated co-morbidities in short stature subjects. Int J Obes Relat Metab Disord (2004) 0.98
Tumor necrosis factor modulates epidermal growth factor receptor phosphorylation and kinase activity in human tumor cells. Correlation with cytotoxicity. J Biol Chem (1989) 0.97
Bcl-2 inhibits p53 nuclear import following DNA damage. Oncogene (1997) 0.97
Fitness to drive in patients with cirrhosis and portal-systemic shunting: a pilot study evaluating driving performance. J Hepatol (1994) 0.97
An evaluation of the costs, effectiveness and quality of renal replacement therapy provision in renal satellite units in England and Wales. Health Technol Assess (2005) 0.97
International Commission for Protection Against Environmental Mutagens and Carcinogens. Oxidative DNA damage--the effects of certain genotoxic and operationally non-genotoxic carcinogens. Mutat Res (1994) 0.97
Diversity of lipid-based polyene formulations and their behavior in biological systems. Eur J Clin Microbiol Infect Dis (1997) 0.96
Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. J Clin Oncol (1989) 0.96
p53-mediated apoptosis prevents the accumulation of progenitor B cells and B-cell tumors. Cell Death Differ (2009) 0.96
Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Blood (1999) 0.95
Stimulation of macrophage protease secretion via liposomal delivery of muramyl dipeptide derivatives to intracellular sites. Immunology (1984) 0.95
Improving outcomes from acute kidney injury (AKI): Report on an initiative. Int J Artif Organs (2007) 0.95
Scaling and universality in heart rate variability distributions. Physica A (1998) 0.95
Phenoxodiol, a novel isoflavone derivative, inhibits dimethylbenz[a]anthracene (DMBA)-induced mammary carcinogenesis in female Sprague-Dawley rats. Eur J Cancer (2003) 0.95
Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. Aliment Pharmacol Ther (2013) 0.95
GRB2: a pivotal protein in signal transduction. Semin Oncol (2001) 0.94
Acute renal failure following poisonous snakebite. Am J Kidney Dis (1984) 0.94
The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literature. J Neurooncol (2001) 0.93
Association of chronotropic incompetence with echocardiographic ischemia and prognosis. J Am Coll Cardiol (1998) 0.92
Mutant Bik expression mediated by the enhanced minimal topoisomerase IIalpha promoter selectively suppressed breast tumors in an animal model. Cancer Gene Ther (2006) 0.92
Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis. Ann Neurol (1994) 0.92